Better Buy: DexCom or Abbott Labs?

When it comes to relatively stable healthcare growth stocks, DexCom (NASDAQ: DXCM) and Abbott Laboratories (NYSE: ABT) just might fit the bill. Worth around $61 billion, the continuous glucose monitor (CGM) specialist DexCom is small compared to medical device giant Abbott's market cap of $228 billion -- and it's no wonder why, because Abbott makes everything from CGMs to COVID tests and even surgical tools.

Still, both companies are profitable and growing at a steady clip, and neither faces any obvious obstacles to their continued success. To figure out which of the pair is a better stock to buy today, let's investigate one perspective on each.

Image source: Getty Images.

Source Fool.com